Navigation Links
Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
Date:8/7/2008

HOPKINTON, Mass., Aug. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, August 14th, 2008 at 9:00am EDT to review the second quarter ending June 30, 2008 and discuss other matters related to the Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

To access the conference call, please dial 877-879-6201 for domestic and 719-325-4816 international. The code for this conference call is 4315502. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Thursday, August 28th, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. Cethrin, a recombinant- protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including b
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
2. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
3. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
4. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
7. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
10. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
11. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Austin, TX (PRWEB) September 30, 2014 ... for Facial Plastic Surgery, has been approved to be ... of Facial Plastic and Reconstructive Surgery (AAFPRS) fellowship program. ... their meeting in Orlando, Florida. , The Educational and ... throughout the medical community. It represents the finest postgraduate ...
(Date:9/30/2014)... 30, 2014 Neuromuscular and central ... the United States and worldwide. It is estimated ... diagnosed each year, adding to the more than ... Approximately 400,000 people in the US are affected ... to these statistics the 2.4 percent of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... caring individuals, National Children’s Oral Health Foundation: ... in grants to non-profit clinical partners. These ... Network and deliver comprehensive educational, preventive and ... Recipients include:,     Just Kids ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Pivotal 5, ... solutions, today announced Life Time – The Healthy Way ... destination for KettleWorX Group Training . KettleWorX Group ... fitness facilities. KettleWorX offers consumers of all fitness levels ... fun and effective manner. The rollout to Life Time ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Herceptin is the best drug ... and should remain the standard of care for that ... long-term clinical trial. HER2-positive breast cancers tend to ... according to the Mayo Clinic. For the study, ... Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to standard ...
Breaking Medicine News(10 mins):Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3
... blood pressure is well known, however// a new study reports ... published today in the Open Access journal Environmental Health for ... of salt particles can have just the same effect on ... an occupational health hazard for workers in salt factory. It ...
... Authority (NPPA) has been working// on bringing down the ... the manufacturers and has finally succeeded. According to NPPA ... bring about a price reduction ranging between 2.14% to ... hearing to explain the reasons for steep price increase ...
... Gengraine Technologies (Avesthagen) of India is collaborating// with ... Developing Countries (IFU) of Germany for Osteoporosis research. ... euro. Avesthagen said “"The alliance will cover diagnosis, ... disorders.” The research studies related to menopause linked ...
... patients with diastolic heart failure increases// the survival rate ... ,William C. Little and his research team from ... heart failure (DHF) treated with statins has better survival ... failure patients published in the Journal Circulation: Journal of ...
... For the elderly population, adjusting to the raising temperatures// in ... heat that may affect the elderly people are heat exhaustion ... Health Letter from the Harvard Medical School had given some ... a little easier during the summers. ,In addition to ...
... article reviewing the research carried out so far into the ... revealed that a new phase III trial is scheduled to ... CoQ10 has escalated, causing soaring prices and reports of fake ... to have been triggered by the publication of Shults’ earlier ...
Cached Medicine News:Health News:Hypertension can be caused by Inhalation of Salt 2Health News:Hypertension can be caused by Inhalation of Salt 3Health News:Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients 2Health News:Elderly People Needs To Tackle The Heat Effectively 2Health News:New Study to look at the Beneficial Effects of Coenzyme Q10 on Parkinson’s disease 2
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
(Date:9/30/2014)... Netherlands , Sept. 30, 2014  eHealth, ... phone storage and access of this information, has ... Slot , however, that has not translated into ... http://photos.prnewswire.com/prnh/20140929/149122 Photo - http://photos.prnewswire.com/prnh/20140929/149123 ... the past few years developing MWD® Health Manager ...
(Date:9/30/2014)... 30, 2014 It is evident from the industry ... not performing upto expectations due to the lack of promotional ... the intake of omega-3 fatty acids. Among omega-3 ingredient sources ... oil, attributed to the large vegetarian population in ... fatty acid (PUFAs) ingredients is in growth stage of its ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... FRANCISCO, Oct. 29 Medivation, Inc. (Nasdaq: MDVN ... webcast with management to discuss third quarter 2010 financial results ... at 4:30 p.m. Eastern Time. A press release for the ... markets close on November 5, 2010. Interested ...
... N.Y., Oct. 29 Henry Schein, Inc. (Nasdaq: ... to office-based practitioners, today reported record financial results for the ... the third quarter of 2010 were $1.9 billion, an increase ... consists of 16.4% growth in local currencies and a decline ...
Cached Medicine Technology:Henry Schein Reports Record Third Quarter Results 2Henry Schein Reports Record Third Quarter Results 3Henry Schein Reports Record Third Quarter Results 4Henry Schein Reports Record Third Quarter Results 5Henry Schein Reports Record Third Quarter Results 6Henry Schein Reports Record Third Quarter Results 7Henry Schein Reports Record Third Quarter Results 8Henry Schein Reports Record Third Quarter Results 9Henry Schein Reports Record Third Quarter Results 10Henry Schein Reports Record Third Quarter Results 11
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: